The Clearity Foundation Has Joined OCRA
Together, we’re expanding support, education, and resources for the gynecologic cancer community.
Strengthening Support Through Partnership
Ovarian Cancer Research Alliance (OCRA), the world’s leading ovarian and gynecologic cancer nonprofit, is proud to announce that The Clearity Foundation has combined with OCRA. This important development brings together two of the most respected organizations in the ovarian cancer field, combining OCRA’s leading research, advocacy, and patient support programs with Clearity’s focus on scientific education and support for women and families facing an ovarian cancer diagnosis.
Please explore the resources below to learn more about the expanded support and tools now available.
Support & Resources
Research
Center for Public Policy
Get Involved
About
Related Topics
The Overview: December 2025
Friends: This has been a pivotal year for Ovarian Cancer Research Alliance (OCRA), defined by powerful forward momentum—from launching the Global Ovarian Cancer Research Consortium to preparing the Community Accelerated Research Exchange for its debut, expanding essential support and education programs, and establishing our new Center for Public Policy. These developments, along with the progress highlighted below, signal a turning … Continued
The Overview: November 2025
Friends, As we approach the end of the year, one thing stands out above all else: this is a moment of unprecedented opportunity to accelerate progress against ovarian and all gynecologic cancers. And thanks to you, OCRA is rising to meet that moment — driving innovation, expanding support, and providing the community that so many … Continued
OCRA Board Member Laura Shawver, PhD, Named to Fierce 50 of 2025
Ovarian Cancer Research Alliance (OCRA) congratulates board member Laura Shawver, PhD, on her selection to the Fierce 50 of 2025, a leading industry award from Fierce Life Sciences recognizing individuals and organizations advancing what’s possible in health, science and patient care. Dr. Shawver was selected for her long-standing leadership in oncology research and drug development, … Continued